Utilization of emicizumab in acquired hemophilia A: A case report

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Acquired Hemophilia A (AHA) is a rare autoimmune disorder associated with the development of autoantibodies against factor VIII (FVIII). Although obtaining hemostatic control through the use of recombinant factor VIIa, activated prothrombin complex concentrate and recombinant porcine FVIII are cornerstones in the clinical management of AHA, these therapies have several disadvantages, including a higher risk for the development of thromboembolic events, unpredictable efficacy and short half-lives. While emicizumab has been FDA licensed for use in bleeding prophylaxis for patients with Congenital Hemophilia A (CHA) with and without inhibitors, it has not been approved for use in AHA, with only a few reports describing its use in this context. Case report: We report our experience with the use of emicizumab in an 83-year old male with AHA, complicated by the onset of atrial fibrillation following admission, drug-induced thrombocytopenia, infectious complications, and the identification of a low-grade lymphoproliferative disorder, in which emicizumab prophylaxis was used for bleeding prophylaxis in the context of persistently elevated inhibitor titers without evidence of thrombotic events or thrombotic microangiopathy.

Original languageEnglish (US)
Article number103457
JournalTransfusion and Apheresis Science
StateAccepted/In press - 2022


  • Acquired hemophilia
  • Autoantibodies
  • Emicizumab
  • Factor VIII inhibitor
  • Hemophilia. A

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Utilization of emicizumab in acquired hemophilia A: A case report'. Together they form a unique fingerprint.

Cite this